NEW ORLEANS, March 24 (Reuters) - The drug-coated stent made by Abbott Laboratories Inc. demonstrated superiority over Boston Scientific Corp's top-selling Taxus stent, according to results of a ...

- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding - XIENCE is the most used ...

PARIS, France—Firehawk, a sirolimus-eluting stent featuring abluminal grooves and a biodegradable polymer, matches the safety and efficacy of the Xience everolimus-eluting stent over 2 years of follow ...

LONDON (MarketWatch) -- Abbott ABT, +1.27% said it's going to study the Xience stent in women with previously untreated coronary artery lesions. Each year, more women than men die of cardiovascular ...

CHICAGO, June 23 (Reuters) - Abbott Laboratories on Tuesday said European regulators approved a new, more flexible version of its Xience drug-eluting stent that is designed for easier placement in the ...

They say if it ain’t broke, don’t fix it, but Abbott just can’t seem to resist making regular additions to its longstanding line of Xience stents. The product family received its first regulatory ...

NATIONAL HARBOR, MD—At 3 years, the bioresorbable-polymer Orsiro stent maintains an advantage over the durable-polymer Xience, according to new data from the BIOFLOW V study. Compared with PCI ...

- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ...

September 25, 2009 (San Francisco, California) — With results that back up those of SPIRIT IV, a second randomized controlled trial comparing the Xience V everolimus-eluting stent (Abbott) with a ...

The US Food and Drug Administration (FDA) has approved 1-month — as short as 28 days — dual antiplatelet therapy (DAPT) labeling for Xience stents in patients at high risk for bleeding, Abbott ...

SAN DIEGO -- The bioresorbable-polymer Orsiro stent continued to outperform the durable-polymer Xience in randomized data going out almost 2 years. Patients who got the Orsiro in the BIOFLOW V trial ...

Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – ...